Botensilimab/balstilimab clinical responses in refractory sarcomas presented at esmo 2024

Lexington, mass.--(business wire)--agenus inc. (“agenus”) (nasdaq: agen), a leader in developing novel immunological agents to treat various cancers, presented data today at the european society for medical oncology (esmo) congress held in barcelona, spain. the data from a phase 1 study of botensilimab (bot), an investigational fc-enhanced ctla-4 inhibitor, in combination with balstilimab (bal), an investigational pd-1 antibody, showed clinical activity in patients with refractory sarcomas, a p.
AGEN Ratings Summary
AGEN Quant Ranking